Susana Rodrigues
@RodriguesSu24
Followers
622
Following
5K
Media
60
Statuses
525
Hepatologist at the Swiss Liver Center, Bern. Interests: Cirrhosis, ALD. Travel and meeting new people. 🇵🇹🇺🇸🇨🇭
Bern, Schweiz
Joined March 2017
⏳ Just 5 months left for #BavenoVIII! 🗓️ 27-28 March 2026 (👶 Pediatric Symposium: 29 March) 📍 Baveno, Italy 🌐 The event will take place in a hybrid formula — both in person and online. 🧠 Call for abstracts is now open! 🔗 More info at: https://t.co/5tL0wP7mQF 🧵
1
8
9
Sarcopenia is common in cirrhosis So you should: 1. Recognize malnutrition 2. Address malnutrition 3. Promote exercise 4. Even supplement testosterone But don’t screen for it Not an independent mortality predictor https://t.co/brgRuJgtKu
3
39
161
Sepsis is a life-threatening, heterogeneous disorder involving a dysregulated immune response to infection. Research to identify subtypes and targeted therapies for host dysregulation is ongoing. Read the full review: https://t.co/LONaEm11Nu
5
199
464
#GUTImage from the #GUTCommentary by Dr Iuliana Pompilia Radu on "Is mailed outreach and patient navigation a perfect solution to improve HCC screening?" via https://t.co/vQ5bP0f8N7
#HCC
1
1
3
On 9th May I will take over as the 1st female Secretary General @EASLnews. I am looking for a partner to join me on my leadership journey and join our global hepatology platform🌎 E - Education A - Advocacy S - Science L - Leadership DM or 📞 for an informal chat. #livertwitter
11
37
146
Can we start NSBBs based only on non-invasive tests?🤔 🔥 Check out our new paper addressing this issue in the unique PREDESCI trial cohort 🔥 Thank you @docberza and @jaumebosch9 for the opportunity to work with this wonderful study group @BavenoCoop
journal-of-hepatology.eu
Whether non-invasive tests (NITs) can accurately select patients with cirrhosis requiring non-selective beta-blockers (NSBBs) for clinically significant portal hypertension (CSPH) and prevention of...
3
13
49
✅ interested in factors modulating cirrhosis regression after control of the etiology? ➡️ Brand new in JHep! Metabolic phenotyping of patients with Advanced Chronic Liver Disease for better characterization of Cirrhosis Regression @yulymendozab
1
10
35
I’m really looking forward to starting this journey - it’s a great honor serving in the team of senior editors for the @JHepatology together with a fantastic group of colleagues! @EASLnews @MedFacultyUniBE @inselgruppe
5
3
43
Consumo de álcool mata 2,6 milhões de pessoas por ano
sicnoticias.pt
Apesar do consumo por parte das mulheres ter aumentado nos últimos anos, os homens continuam a ser os mais afetados pelo alcoolismo e representam mais de 70% das mortes.
5
4
9
🔔 Reminder: Hepatologia em Rede Encontra-se a decorrer um estudo sobre a epidemiologia da Colangite Esclerosante Primária em Portugal, que não é completamente conhecida. 👉 Para participar neste estudo, envie e-mail para: hepatologiaemrede@apef.com.pt
0
1
2
Amplía tus conocimientos en la metodología para el estudio de las enfermedades hepáticas cursado esta asignatura troncal. De la mano de los mejores profesores y con material docente plenamente actualizado. No te quedes sin tu plaza! Inicio de curso el 03/10!
0
15
20
Commercial determinants of health! The Killers: Alcohol, tobacco, ultra-processed foods and fossil fuels cause 2.7 million deaths in the Europe every year We know why, we know how to change it - yet nothing happens?? @EASLEUAffairs @SagiZelber @JVLazarus WHO report 👇
📢 Landmark new report: Commercial Determinants of NCDs 📢 Chronic diseases account for 90% of deaths in the Region. New research highlights how big industries fuel them, obstructing health policy and targeting the vulnerable. https://t.co/8bns6JeN9e
#NCDs #CDoH #SDGs #R2F
0
8
18
New content online: Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement https://t.co/N2lLGKJCLa
1
16
49
Key takeaways from @BavenoCoop Track Hub: 1⃣ Become a member, it´s free‼️ 2⃣ Requirements❓Passion for PH research regardless of your expertise 3⃣ Join via our website: https://t.co/YTPcR7E1KP 4⃣ Upload: CV and motivational letter (1 page max) 5⃣ Sponsorships warmly welcomed‼️
2
9
25
Packed Baveno Cooperation Track Hub at the #EASLCongress ! Welcoming new members interested in portal hypertension - we particularly welcome young investigators! Check out pur website and learn how to become member @BavenoCoop
https://t.co/FAt6liEL2k
0
12
43
0
3
21
New content online: Endogenous ethanol production in health and disease https://t.co/O0UkunwZjf
1
9
31
Getting ready for a great EASL ILC - don’t forget to join the Baveno Cooperation Track Hub on Saturday! @ggarciatsao @ReibergerThomas @crisripol @jaumebosch9 @EltonDajti @RodriguesSu24 @EASLnews
0
8
40
In 83,825 patients with obesity, semaglutide (vs. other anti-obesity meds) associated with 50%-56% lower risk of alcohol use disorder. Findings replicated patients with type 2 diabetes @NatureComms More compelling data, await RCT results https://t.co/Mebua6tdG6
nature.com
Nature Communications - Anecdotal reports from patients prescribed semaglutide describe a reduced desire to drink. Here, the authors show that semaglutide is associated with a 50%-56% reduced risk...
1
9
35
👉Join the Baveno Cooperation at the EASL ILC in Milano‼️ 🗓️Two events, both on Saturday June 8 1⃣ EASL-CLIF Joint Future of Hepatology Session: Decompensated Cirrhosis 🕒 08:30-09:45 AM, Room: Brown 3 🔗 https://t.co/zMqOr0cQ7D and ... 👇
1
5
11